endo international plc (ENDP:NASDAQ GS)
Ivan P. Gergel M.D.
Former Chief Scientific Officer and Executive Vice President of Research & Development, Endo International plc
|Age||Total Calculated Compensation||This person is connected to 47 board members in 4 different organizations across 7 different industries.|
See Board Relationships
As of Fiscal Year 2013
Dr. Ivan P. Gergel, M.D., has been the Chief Medical Officer and Senior Vice President of Drug Development at Nektar Therapeutics since May 19, 2014. Dr. Gergel has more than 25 years of pharmaceutical leadership and drug development experience. He served as the Chief Scientific Officer and Executive Vice President of Research & Development at Endo International Plc, Endo Health Solutions Inc. and Endo Pharmaceuticals Solutions Inc. from April 29, 2008 to March 31, 2014, ...
Minerva HousePhone: 353 1 268 2000
Dublin, Co. Dublin 4
Board Members Memberships*
Executive Vice President of Research & Development
Director and Member of Technology & Product Development Committee
University of Pennsylvania - The Wharton School
Royal Free and University College Medical School
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Michael W. Aguiar||Chief Executive Officer, President and Director|
|Peter M. Hecht Ph.D.||Co-Founder, Chief Executive Officer and Director|
Ironwood Pharmaceuticals, Inc.
|James A. Schoeneck||Chief Executive Officer, President and Director|
|Peter S. Greenleaf||Chief Executive Officer and Director|
Sucampo Pharmaceuticals, Inc.
|Daniel J. Abdun-Nabi||Chief Executive Officer, President, Director, Member of Strategic Operations Committee and Member of Pricing Committee|
Emergent BioSolutions, Inc.
|$1.2M||Compensation as of Fiscal Year 2014.|